Modafinil Dosing During Long-Term Treatment of Excessive Sleepiness in Narcolepsy and Obstructive Sleep Apnea

CHEST Journal ◽  
2004 ◽  
Vol 126 (4) ◽  
pp. 903S
Author(s):  
Jonathan R. Schwartz ◽  
Max Hirshkowitz ◽  
Wolfgang Schmidt-Nowara
2015 ◽  
Vol 37 (1) ◽  
pp. 395-409 ◽  
Author(s):  
Hosung Kim ◽  
EunYeon Joo ◽  
Sooyeon Suh ◽  
Jae-Hun Kim ◽  
Sung Tae Kim ◽  
...  

CHEST Journal ◽  
2010 ◽  
Vol 138 (4) ◽  
pp. 886A ◽  
Author(s):  
Konrad E. Bloch ◽  
Tsogyal D. Latshang ◽  
Yvonne Nussbaumer-Ochsner ◽  
Malcolm Kohler ◽  
Robert Thurnheer ◽  
...  

2010 ◽  
Vol 33 (8) ◽  
pp. 844-849 ◽  
Author(s):  
Tsunenori Saito ◽  
Tsunehiro Saito ◽  
Shigeyuki Sugiyama ◽  
Kuniya Asai ◽  
Masahiro Yasutake ◽  
...  

Author(s):  
Jean-Louis Pépin ◽  
Richard Schwab ◽  
Colin Shapiro ◽  
Jan Hedner ◽  
Monsoor Ahmed ◽  
...  

Author(s):  
Marta Marin-Oto ◽  
Eugenio E. Vicente ◽  
Jose M. Marin

Obstructive sleep apnea (OSA) is a worldwide highly prevalent disease associated with systemic consequences, including excessive sleepiness, impairment of neurocognitive function and daytime performance, including driving ability. The long-term sequelae of OSA include and increase risk for cardiovascular, cerebrovascular and metabolic syndrome disorders that ultimately lead to premature death if untreated. To ensure optimal long-term outcomes, the assessment and management of OSA should be personalized with the involvement of the appropriate specialist. Most studies have demonstrated inmediate improvement in daytime somnolence and quality of life with CPAP and other therapies, but the effect of long-term treatment on mortality is still under debate. Currently, the long-term management of OSA should be based on a) identifying physiological or structural abnormalities that are treatable at the time of patient evaluation and b) comprehensive lifestyle interventions, especially weight-loss interventions, which are associated with improvements in OSA severity, cardiometabolic comorbidities, and quality of life. In long-term management, attention should be paid to the clinical changes related to a potential reoccurrence of OSA symptoms and it is also necessary to monitor throughout the follow up how the main associated comorbidities evolve.


Sign in / Sign up

Export Citation Format

Share Document